GSK And Affiris Sign An Exclusive Licence And Option Agreement For Therapeutic Alzheimer’s Disease Candidate Vaccines
GlaxoSmithKline Biologicals S.A. (GSK) and AFFiRiS GmbH announced today the execution of a collaboration agreement granting GSK exclusive rights to AFFiRiS’s Alzheimer’s disease vaccine programmes, aimed at treating Alzheimer’s by targeting beta-amyloid.
More: continued here
Filed under: Alzheimer's / Dementia News XML/RSS Feed on October 27th, 2008